In order to provide the most relevant content to the readers of HealthCare Business News, we're asking you to share a little information about who you are, (it takes two seconds and then you're done).
Register
Cerveau Technologies Inc. signs collaboration agreement with Janssen for novel Tau imaging agent
Press releases may be edited for formatting or style | October 17, 2017
Molecular ImagingPET
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Janssen neurodegenerative disease research studies. The parties will collaborate on using [F-18]MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans.
“Cerveau is focused on enhancing access to key technologies that we believe have the potential to advance brain health,” says Rick Hiatt, President and chief executive officer, Cerveau Technologies, Inc.. “We are excited by the opportunity to work with Janssen with the goal of expanding the availability of this novel investigational imaging agent globally throughout the broader scientific community.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
